BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Chinese Patent Office
Teva
McKinsey
Boehringer Ingelheim
Federal Trade Commission
Citi
Medtronic
UBS

Generated: January 20, 2018

DrugPatentWatch Database Preview

ULORIC Drug Profile

« Back to Dashboard

When do Uloric patents expire, and what generic alternatives are available?

Uloric is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and five patent family members in thirty-five countries.

The generic ingredient in ULORIC is febuxostat. There are twenty-five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the febuxostat profile page.
Summary for ULORIC
Drug patent expirations by year for ULORIC
Pharmacology for ULORIC
Medical Subject Heading (MeSH) Categories for ULORIC

US Patents and Regulatory Information for ULORIC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ULORIC
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 40 mg and 80 mg ➤ Subscribe 2/13/2013

International Patents for ULORIC

Supplementary Protection Certificates for ULORIC

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2010 005, C 1020454 Lithuania ➤ Subscribe PRODUCT NAME: FEBUXOSTATUM; REGISTRATION NO/DATE: EU/1/08/447/001-EU/1/08/447/004 20080421
/2010 Austria ➤ Subscribe PRODUCT NAME: FEBUXOSTAT IN DER KRISTALLFORM A; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421
2010 00015 Denmark ➤ Subscribe
2010 00015 Denmark ➤ Subscribe PRODUCT NAME: FEBUXOSTAT; REG. NO/DATE: EU/1/08/447/001-004 20080421
C/GB10/019 United Kingdom ➤ Subscribe SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB10/019 GRANTED TO TEIJIN LIMITED IN RESPECT OF THE PRODUCT FEBUXOSTAT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6408 DATED 14/03/2012 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22/04/2023.
00447 Netherlands ➤ Subscribe PRODUCT NAME: FEBUXOSTAT; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421
2010005,C1020454 Lithuania ➤ Subscribe PRODUCT NAME: FEBUXOSTATUM; REGISTRATION NO/DATE: EU/1/08/447/001-EU/1/08/447/004, 0080421
C015/2010 Ireland ➤ Subscribe SPC015/2010: 20101001, EXPIRES: 20230420
5 Finland ➤ Subscribe
682 Luxembourg ➤ Subscribe 91682, EXPIRES: 20230421
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Queensland Health
Chinese Patent Office
Chubb
Novartis
Federal Trade Commission
QuintilesIMS
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot